Vaxcyte CAO Sells $180,000 in Stock

Insider transaction represents 9.38% decrease in executive's position

Apr. 8, 2026 at 10:26pm

Got story updates? Submit your updates here. ›

An extreme close-up of intricately machined metal gears and levers, conveying a sense of the heavy, institutional machinery that powers the financial markets.An insider transaction at Vaxcyte highlights the complex financial mechanics underlying the biotech industry.San Carlos Today

Vaxcyte, Inc. (NASDAQ:PCVX) Chief Accounting Officer Elvia Cowan sold 3,000 shares of the company's stock on Tuesday, April 7th. The shares were sold at an average price of $60.00, for a total transaction value of $180,000. Following the sale, Cowan still owns 28,975 shares in the company, valued at approximately $1.74 million.

Why it matters

Insider selling can sometimes be a signal of a company's future performance or executive confidence. However, Cowan's sale was executed under a pre-arranged trading plan, which limits the ability to draw conclusions from the transaction.

The details

Cowan's sale represents a 9.38% decrease in her position in Vaxcyte. The company is a clinical-stage biotech focused on developing a new generation of preventive vaccines. Its lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine.

  • The transaction occurred on Tuesday, April 7th, 2026.
  • Cowan also sold 1,892 shares on March 17th and 2,500 shares on March 11th.

The players

Elvia Cowan

Chief Accounting Officer of Vaxcyte, Inc.

Vaxcyte, Inc.

A clinical-stage biotechnology company focused on developing a new generation of preventive vaccines.

Got photos? Submit your photos here. ›

The takeaway

While insider selling can sometimes raise questions, Cowan's sale was part of a pre-planned transaction, limiting the ability to draw conclusions about Vaxcyte's future prospects. The company remains focused on advancing its pipeline of novel vaccine candidates.